Six weeks after Sanofi-Aventis Chief Executive Officer Chris Viehbacher agreed to pay $500 million for a company with 18 employees, the acquisition looks like a bargain.
The experimental drug added by Paris-based Sanofi when it bought BiPar Sciences Inc. of San Francisco prolonged survival in women with an aggressive form of breast cancer by 3.5 months, to 9.2 months, when added to chemotherapy in a study. The finding, presented at the American Society of Clinical Oncology meeting yesterday, was called “a huge bombshell” by Powel Brown, director at the Lester and Sue Smith Breast Center at Baylor College of Medicine in Houston, Texas.
No comments:
Post a Comment